BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 9279502)

  • 1. Breast cancer therapies in development. A review of their pharmacology and clinical potential.
    de Valeriola D; Awada A; Roy JA; Di Leo A; Biganzoli L; Piccart M
    Drugs; 1997 Sep; 54(3):385-413. PubMed ID: 9279502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Metastatic breast cancer: what are the objectives?].
    Salvini P; Ripa C; Ginanni V
    Tumori; 2000; 86(5 Suppl 1):S22-8. PubMed ID: 11195289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
    Sparano JA
    Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life issues in the treatment of metastatic breast cancer.
    Carlson RW
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):27-31. PubMed ID: 9556780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel in combination chemotherapy for metastatic breast cancer.
    Khayat D; Antoine E
    Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New cytotoxic agents and molecular-targeted therapies in the treatment of metastatic breast cancer.
    Awada A
    Forum (Genova); 2002; 12(1):4-15. PubMed ID: 12634907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of adjuvant chemotherapy in the choice of chemotherapeutic treatment of metastatic breast cancer].
    Lopez M; Di Lauro L; Viola G; Conti F; Foggi P; Vici P
    Clin Ter; 2009; 160(6):489-97. PubMed ID: 20198293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evolution of adjuvant chemotherapy of breast cancer from Bonadonna to the taxanes].
    Nagykálnai T
    Magy Onkol; 2002; 46(4):307-13. PubMed ID: 12563352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic treatment of breast cancer. Two decades of progress.
    Seidman AD
    Oncology (Williston Park); 2006 Aug; 20(9):983-90; discussion 991-2, 997-8. PubMed ID: 16986346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
    Moreno-Aspitia A; Perez EA
    Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current trends in pharmacotherapy of breast cancer].
    Boér K
    Orv Hetil; 2002 Apr; 143(14):725-30. PubMed ID: 11975393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of breast cancer: status and future trends.
    Hortobagyi GN
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):101-7. PubMed ID: 7481851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum compounds in the treatment of advanced breast cancer.
    Martín M
    Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of docetaxel into adjuvant breast cancer treatment regimens.
    Hortobagyi GN
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):27-33. PubMed ID: 12108895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in systemic adjuvant therapy of early-stage breast cancer.
    Gradishar WJ; O'Regan RM
    Int J Clin Oncol; 2003 Aug; 8(4):239-47. PubMed ID: 12955580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future perspectives of docetaxel (Taxotere) in front-line therapy.
    Piccart MJ; Di Leo A
    Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-27-S10-33. PubMed ID: 9275004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer.
    Leung PP; Tannock IF; Oza AM; Puodziunas A; Dranitsaris G
    J Clin Oncol; 1999 Oct; 17(10):3082-90. PubMed ID: 10506603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer.
    Estévez LG; Gradishar WJ
    Clin Cancer Res; 2004 May; 10(10):3249-61. PubMed ID: 15161677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Taxanes: impact on breast cancer therapy.
    Bachegowda LS; Makower DF; Sparano JA
    Anticancer Drugs; 2014 May; 25(5):512-21. PubMed ID: 24552749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.